Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

AstraZeneca And Daiichi Sankyo Report Phase 3 Results Showing Datroway's Superiority To Chemotherapy In First-Line Metastatic Triple Negative Breast Cancer

Author: Benzinga Newsdesk | October 06, 2025 03:24am
  • Daiichi Sankyo and AstraZeneca's DATROWAY is the first and only therapy to significantly improve overall survival versus chemotherapy in this patient population
  • DATROWAY also demonstrated a highly statistically significant and clinically meaningful improvement in the dual primary endpoint of progression-free survival
  • Plans for global regulatory submissions are underway

Posted In: AZN DSNKY


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist